The bang for the buck with L is with combos and subsets in multiple cancer types even without combos. The IFR pathway with cancer indication points to this. The question for MHRA, NHS and NICE is how to accomplish best use of funds while granting an approval for GBM/rGBM when not all of these patients will benefit at the same rate as those with other cancer types treated in compassionate use who are likely benefitting much more based on their subset patient characteristics. Enter IFR reimbursement that will focus funds and treatment based on patient characteristics and likelihood of benefit until cost of treatment gets reduced to acceptable for the broader population of qualifying patients. Best wishes.
Market Data 
Markets 
AI
